Detecting and targeting NTRK fusions in NSCLC: a clinical pathway tool

This tool will guide you through the best practices for detection and treatment of NTRK fusions in NSCLC. This interactive pathway provides details on the various assays that can be used to detect NTRK gene fusions, covering both the optimal approach and methods that can be used when the ideal method is not available. Our expert faculty also explain the latest advances in targeted therapies for NTRK fusion-positive NSCLC and provide their recommendations for treatment. The pathway is supplemented by summaries of recent publications to help you remain up to date with the latest clinical trial data.

Register to access

Learning objectives

After completing this activity, you will be able to: 

  • Outline biomarkers that should be tested for in patients with advanced NSCLC
  • Select appropriate strategies to identify NTRK gene fusions in NSCLC
  • Describe advances in therapies for NTRK fusion-positive tumors and evaluate the clinical data supporting their use

Activity overview

This algorithm module is available with video and text. The activity is best supported via a computer or mobile device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari.

Release date: 20th October 2023

Expiration date: 20th October 2024

Estimated time to complete: 30 minutes


In support of improving patient care, this activity has been planned and implemented by HMP Education and Springer Healthcare IME. HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

HMP Education designates this activity for a maximum of 0.5 AMA PRA Category 1 Credits.

How to claim your credits

To claim your credits, you will need to complete the activity, then fill out the short evaluation form at the end of the module. Physicians should claim only the credit commensurate with the extent of their participation in the activity.